Teresa T Cabrera

List of Publications by Year
in descending order

69 papers	5,035 citations	117625 34 h-index	114465 63 g-index
71 all docs	71 docs citations	71 times ranked	4501 citing authors

#	Article	IF	Citations
1	Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Trends in Immunology, 1997, 18, 89-95.	7.5	708
2	Natural history of HLA expression during tumour development. Trends in Immunology, 1993, 14, 491-499.	7.5	432
3	The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunology, Immunotherapy, 2004, 53, 904-10.	4.2	239
4	HLA class I antigen abnormalities and immune escape by malignant cells. Seminars in Cancer Biology, 2002, 12, 3-13.	9.6	233
5	â€œHardâ€•and â€œsoftâ€•lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. International Journal of Cancer, 2010, 127, 249-256.	5.1	232
6	Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: Î²2 -microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens, 2003, 61, 211-219.	1.0	134
7	Mutations of the Î²₂â€microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 1998, 52, 520-529.	1.0	132
8	The HLA crossroad in tumor immunology. Human Immunology, 2000, 61, 65-73.	2.4	129
9	MHC Class I Antigens and Immune Surveillance in Transformed Cells. International Review of Cytology, 2007, 256, 139-189.	6.2	128
10	High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Human Immunology, 1996, 50, 127-134.	2.4	126
11	Hla Class I Antigens in Human Tumors. Advances in Cancer Research, 1995, 67, 155-195.	5.0	121
12	Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics, 2008, 60, 439-447.	2.4	119
13	Role of Altered Expression of HLA Class I Molecules in Cancer Progression. Advances in Experimental Medicine and Biology, 2007, 601, 123-131.	1.6	117
14	Coordinated downregulation of the antigen presentation machinery and HLA class I/Î²2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. International Journal of Cancer, 2005, 113, 605-610.	5.1	116
15	Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunology, Immunotherapy, 2002, 51, 389-396.	4.2	105
16	Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. , 1999, 83, 91-97.		104
17	Analysis of HLA expression in human tumor tissues. Cancer Immunology, Immunotherapy, 2003, 52, 1-9.	4.2	98
18	Presence of hpv 16 sequences in laryngeal carcinomas. International Journal of Cancer, 1990, 46, 8-11.	5.1	97

#	Article	IF	Citations
19	Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunology, Immunotherapy, 2005, 54, 400-406.	4.2	88
20	High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens, 1998, 52, 114-123.	1.0	84
21	HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunology, Immunotherapy, 2007, 56, 709-717.	4.2	78
22	Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics, 2004, 56, 244-53.	2.4	77
23	Frequent loss of heterozygosity in the Î²2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics, 2011, 63, 65-71.	2.4	75
24	Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferonâ€mediated rejection genes. International Journal of Cancer, 2012, 131, 387-395.	5.1	75
25	Expression of HLA G in human tumors is not a frequent event. , 1999, 81, 512-518.		65
26	Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunology, Immunotherapy, 2005, 54, 858-866.	4.2	62
27	Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Human Immunology, 2000, 61, 1001-1012.	2.4	58
28	LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas. Immunogenetics, 2006, 58, 503-510.	2.4	56
29	Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunology, Immunotherapy, 2008, 57, 1727-1733.	4.2	56
30	HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunology, Immunotherapy, 2009, 58, 1507-1515.	4.2	53
31	Biological Implications of HLA-DR Expression in Tumours. Scandinavian Journal of Immunology, 1995, 41, 398-406.	2.7	52
32	Bacillus Calmetteâ€Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class Iâ€deficient tumor cells. International Journal of Cancer, 2011, 129, 839-846.	5.1	52
33	Can the HLA phenotype be used as a prognostic factor in breast carcinomas?. International Journal of Cancer, 1991, 47, 146-154.	5.1	50
34	HLA class I expression and HPVâ€16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens, 1993, 41, 65-71.	1.0	46
35	Characterization of a gastric tumor cell line defective in MHC class I inducibility by both Î±â€and Î³â€interferon. Tissue Antigens, 1996, 47, 391-398.	1.0	45
36	High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Human Immunology, 2000, 61, 499-506.	2.4	43

#	Article	IF	Citations
37	Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens, 2006, 68, 303-310.	1.0	35
38	Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. Cancer Immunology, Immunotherapy, 2016, 65, 47-59.	4.2	35
39	Analysis of HLAâ€“ABC locus-specific transcription in normal tissues. Immunogenetics, 2010, 62, 711-719.	2.4	33
40	A Transcriptome-proteome Integrated Network Identifies Endoplasmic Reticulum thiol oxidoreductase (ERp57) as a Hub that Mediates Bone Metastasis. Molecular and Cellular Proteomics, 2013, 12, 2111-2125.	3.8	32
41	Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Seminars in Cancer Biology, 2002, 12, 15-24.	9.6	31
42	Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours. Tissue Antigens, 2007, 69, 220-226.	1.0	31
43	HLA class I expression in bladder carcinomas. Tissue Antigens, 2003, 62, 324-327.	1.0	30
44	A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics, 2001, 53, 606-610.	2.4	29
45	High frequency of HLA-B44 allelic losses in human solid tumors. Human Immunology, 2003, 64, 941-950.	2.4	26
46	Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens, 2007, 69, 264-268.	1.0	26
47	Molecular analysis of MHC-class-I alterations in human tumor cell lines. International Journal of Cancer, 1991, 47, 123-130.	5.1	25
48	HLA molecules in basal cell carcinoma of the skin. Immunobiology, 1992, 185, 440-452.	1.9	25
49	Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression. Cancer Immunology, Immunotherapy, 2000, 48, 684-690.	4.2	21
50	Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens, 2010, 75, 110-118.	1.0	21
51	Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunology, Immunotherapy, 2011, 60, 869-882.	4.2	19
52	HLA Class I and II Expression in Rhabdomyosarcomas. Immunobiology, 1991, 182, 440-448.	1.9	18
53	K-ras mutations (codon 12) are not involved in down-regulation of mhc class-i genes in colon carcinomas. International Journal of Cancer, 1990, 46, 426-431.	5.1	17
54	Loss of HLA Heavy Chain and beta2-Microglobulin in HLA Negative Tumours. Scandinavian Journal of Immunology, 1991, 34, 147-152.	2.7	17

#	Article	IF	Citations
55	Looking for HLA-G expression in human tumours. Journal of Reproductive Immunology, 1999, 43, 263-273.	1.9	13
56	? 2 -microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors. International Journal of Clinical and Laboratory Research, 2000, 30, 87-92.	1.0	13
57	Class II HLA Antigen Expression in Familial Polyposis Coli is Related to the Degree of Dysplasia. Immunobiology, 1990, 180, 138-148.	1.9	11
58	A Monoclonal Antibody GR2110 Reactive With a P24 Antigen Present in a Subgroup of Acute Lymphoid Leukemias. Hybridoma, 1985, 4, 369-378.	0.6	9
59	Cytotoxic effects of alkaline tetrasodium EDTA irrigating solutions. Journal of Oral Science, 2020, 62, 285-287.	1.7	5
60	Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis. Journal of Oncology, 2021, 2021, 1-9.	1.3	4
61	HLA Class I Expression, Tumor Escape and Cancer Progression. Current Cancer Therapy Reviews, 2008, 4, 105-110.	0.3	3
62	MHC Class I Antigens In Malignant Cells. , 2013, , .		3
63	HLA-DRB1 âˆ— 16:01 and HLA-DQB1 âˆ— 05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma. Journal of Oncology, 2021, 2021, 1-7.	1.3	3
64	Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. International Journal of Cancer, 1999, 83, 91-97.	5.1	3
65	â€œHardâ€•and â€œsoftâ€•lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. , 2010, 127, 249.		1
66	Upmodulation by estrogen of HLA class I expression in breast tumor cell lines. Human Immunology, 1994, 39, 129.	2.4	0
67	HLA Class I Expression in Human Cancer. , 2013, , 13-30.		0
68	MHC Class I Antigens and the Tumor Microenvironment. , 2013, , 253-286.		0
69	Overview of MHC Class I Antigens. , 2013, , 1-11.		0